Circio and Neoregen Biotech today announce the start of a research collaboration
on novel circular RNA (circRNA) therapeutics based on CircioŽs proprietary
circVec technology. The parties will test the ability of NeoregenŽs NICT
(Neoregen Intra-Cellular delivery Technology) delivery system to enhance
cellular uptake and nuclear transfer of circVec vectors compared to commercially
available delivery technologies.

circRNA is an emerging class of novel RNA-therapeutics that offers improved
durability and enhanced protein expression compared to mRNA. Due to these
potentially significant advantages, circRNA has attracted significant funding
and partnering transactions in the last two years. Circio is the leader in
vector-delivery of circRNA based on its proprietary circVec technology, a DNA
-based vector platform that enables high-yield intra-cellular expression of
circRNAs for therapeutic applications. Intra-cellular expression of circRNA
increases durability and protein expression compared to both synthetic LNP
-delivered circRNA or mRNA, thereby offering potentially significant advantages
in gene therapy, vaccines and cancer. The circVec technology is based on over
ten years of research and is composed of a modular genetic cassette design for
efficient biogenesis of multifunctional circRNAs that can be adapted and applied
to multiple purposes.

Neoregen's NICT platform technology is a novel peptide-based chemistry suitable
for delivery of nucleic acid therapeutics. This technology enables the
development of drugs for targets that were previously inaccessible using
conventional methods and can also significantly improve the efficacy and safety
of existing treatments. While many previously developed cell-penetrating
peptides failed to achieve Endosome Escape, a crucial step for drug delivery,
Neoregen's technology has demonstrated superior results in animal experiments
compared to competitors. Currently, discussions are underway for various forms
of collaboration in this regard.

Dr. Jeong-Min, Seo CEO of Neoregen Biotech, stated, "Through this collaboration,
we believe our peptide-based next-generation drug delivery system can overcome
the limitations of existing mRNA-based therapeutic technologies and provide
better delivery of innovative novel RNA therapeutics, bringing innovation to the
biopharma industry."

Dr. Erik Digman Wiklund, CEO of Circio Holding ASA, added: "Synthetic DNA
vectors hold major promise as durable protein replacement therapies for genetic
diseases. However, efficient delivery to target tissues, and uptake into the
cell nucleus, remain a technical challenge. Neoregen offers a unique solution to
tackle this problem, and we are very excited to collaborate and develop novel
NICT-delivered circVec therapeutic candidates."

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for cancer, vaccines, rare disease, protein replacement
therapy and cell therapy. The proprietary circVec technology is based on a
modular genetic cassette design for efficient biogenesis of multifunctional
circRNA that can be deployed for many purposes. The most advanced concept,
circAde, builds on the companyŽs validated adenovirus platform to deliver
circRNA for durable expression of therapeutic proteins directly into cancer
cells. This unique approach is the only currently known circRNA program capable
of targeting solid tumors. The circVec platform has broad potential
applications, and CircioŽs strategy is to generate one or more lead candidates
for in house development in specific disease indications and in parallel seek
partnerships for other technical applications and therapeutic areas. The circRNA
R&D activities are being conducted by the wholly owned subsidiary Circio AB
based at the Karolinska Institute in Stockholm, Sweden.

In addition to Circio's circRNA program, the Company's' clinical stage
immunotherapy programs are designed to activate the patientŽs own immune system
to fight cancer cells and provide benefit to patients with no or few treatment
alternatives. ONCOS-102 has demonstrated an excellent safety profile, strong
immune responses and clinical efficacy in several cancer types in Phase 1/2
studies, both as monotherapy and in combinations with checkpoint inhibitors or
standard-of-care chemotherapy. A phase 2 trial to confirm the therapeutic
activity of ONCOS-102 in melanoma patients resistant to PD-1 checkpoint
inhibitor treatment has been designed, and Circio is seeking external financing
and/or partnerships to continue the clinical development.

Circio's second clinical stage program is an immunotherapy targeting KRAS driver
mutations. TG01 has previously shown robust immune responses and encouraging
clinical benefit in surgically resected pancreatic cancer and is currently being
tested in two clinical trials in RAS-mutated pancreatic cancer and multiple
myeloma in the USA and Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating broad future optionality for
the TG01 program at low cost to Circio.